Evidence map›Paper›PMID 22249375›Full record

ArticleClinical rheumatology2012

Potential of the HAQ score as clinical indicator suggesting comprehensive multidisciplinary assessments: the Swedish TIRA cohort 8 years after diagnosis of RA.

Ingrid Thyberg, Ö Dahlström, M Björk, P Arvidsson, M Thyberg

2 registry-linked trialsAbstract readEvaluation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06568029 completednot on this mapstarted 2024, after this paper: background citation

Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease

TypeobservationalSponsorKarolinska InstitutetRan2024 to 2024Enrolled77,651ConditionsRheumatoid Arthritis, Polyarthritis, Psoriatic Arthritis, Ankylosing SpondylitisArmsQuestionnaire
NCT07580092 completednot on this mapstarted 2023, after this paper: background citation

Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease

TypeobservationalSponsorKarolinska InstitutetRan2023 to 2026Enrolled6,967ConditionsAnkylosing Spondylitis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, PolyarthritisArmsEQ-5D-5L
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Construct validity and responsiveness of EQ-5D-3L and EQ VAS in psoriatic arthritis: an evaluation based on the Swedish Rheumatology Quality Register.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Ingrid ThybergAIR/Rheumatology Unit, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. ingrid.thyberg@lio.se
Ö Dahlström
M Björk
P Arvidsson
M Thyberg
Jönköping University · SELinköping University · SELinköping University Hospital · SEÖrebro University · SESwedish Institute · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study explores the potential of the health assessment questionnaire (HAQ) score as a clinical indicator that can be used to suggest comprehensive multidisciplinary assessments, by relating it to more general aspects of disability. In a cohort of 132 patients with early RA (mean age 55, 68% women), 28 joint count Disease Activity Scores (DAS-28), HAQ, and Short Form 36 (SF-36) scores were registered at annual follow-up visits 8 years after diagnosis. The patients were tentatively sub-grouped into a high-HAQ group (HAQ ≥ 1 at the 8-year follow-up) and a low-HAQ group. The high-HAQ group, comprising 36% of the cohort, had a higher mean HAQ score at inclusion and beyond at all visits compared to the low-HAQ group, and 24% of all individual patients in the high-HAQ group had a HAQ score ≥ 1 at inclusion. Although the DAS-28 improved in both groups, patients in the high-HAQ group also had significantly more persistent disability according to the SF-36: five scales at each follow-up visit and all eight scales at the majority of the visits. Individual RA patients with HAQ ≥ 1 probably have considerable persistent disabilities according to the SF-36. The HAQ score could be used as a clinical indicator suggesting comprehensive multidisciplinary assessments of the components of disability and corresponding interventions, in addition to the established use of HAQ at group levels and in parallel with the medication strategy based on DAS-28.

Indexed as

Interdisciplinary CommunicationSeverity of Illness IndexActivities of Daily LivingAdultArthritis, RheumatoidDisability EvaluationFemaleHealth StatusHumansMaleMiddle AgedPredictive Value of TestsSurveys and Questionnaires

Identifiers

PMID22249375
OpenAlexW2092347929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.